HLT

Committed to driving heart
valve disease therapy forward
Designing technology
compatible with the native
aortic valve anatomy
 

Designing third-generation transcatheter aortic valve replacement technology

HLT®, Inc., a clinical stage medical device company, is committed to driving the treatment of valvular heart disease forward by developing third-generation transcatheter aortic valve replacement technology.

The new HLT Transcatheter Valve System is intended to restore valve performance with a delivery system designed to provide:


News & Events

HLT, Inc. featured in Star Tribune article.

HLT, Inc. is participating in cardiovascular conferences and events.